Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Acquires China Rights to Novel Immunoncology Candidate from Alector

publication date: Mar 26, 2020

Suzhou Innovent Bio acquired China rights to an anti-SIRP-alpha antibody from Alector, a South San Francisco biotech. AL008 is designed to inhibit the ability of macrophages to interfere with the immune response around tumors. It antagonizes the CD47-SIRP-alpha pathway by degrading the inhibitory receptor on macrophages while engaging Fc gamma to promote immuno-stimulatory pathways, increasing the immune attack on the tumor. In pre-clinical studies, the molecule has shown activity in myeloid and lymphoid cancers. Innovent will lead China development of the molecule and have manufacturing rights. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China